A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia
With a regenerative, patient-centered approach, we help restore confidence, intimacy, and optimal function, so you can feel your best at any stage of life
BioXconomy recently reported on a landmark study that showed GLP-1s cut mortality and hospitalization rates from heart failure by 40%, potentially independent of their weight loss effects
Because microdosing starts at a very low level, its designed to reduce the chance of more disruptive side effects that can occur at higher doses
dbGSH: a database of S-glutathionylation
